



NTP
National Toxicology Program

Report on Carcinogens Draft Substance Profile on Captafol

Gloria D. Jahnke, DVM
National Institute of Environmental Health Sciences
NTP Board of Scientific Counselors Meeting
Research Triangle Park, NC
February 24, 2009






NTP
National Toxicology Program

Captafol

CAS No. 2425-06-1



3a,4,7,7a-tetrahydro-2-[(1,1,2,2-tetrachloroethylthio)-1*H*-isoindole-1,3-(2*H*)-dione (CAS),
difolatan (JMAF), 1,2,3,6-tetrahydro-N-(1,1,2,2-tetrachloroethylthio)phthalimide (IUPAC),
N-(1,1,2,2-tetrachloroethylthio)cyclohex-4-ene-1,2-dicarboximide (IUPAC),
3a,4,7,7a,tetrahydro-N-(1,1,2,2-tetrachloroethanesulfenyl)phthalimide (IUPAC)





Objectives

To present the science that supports the preliminary listing recommendation for captafol in the 12th RoC as *Reasonably Anticipated to be a Human Carcinogen*

- Information on use and exposure in US
- Cancer studies in humans and experimental animals
- Mechanistic evidence that supports the recommendation



Uses

- Non-systemic fungicide used on fruits, vegetables, other plants, and timber products in US from 1961 until 1987
- Legal use of existing stocks until 1999, EPA restricted use to onions, potatoes, and tomatoes
- These remaining tolerances revoked by EPA in 2006



Exposure

- Potential exposure from consumption of imported food products containing residues
- Dermal, oral, and inhalation absorption
- Significant past occupational and environmental exposure



Human Cancer Studies

- Data from studies inadequate to evaluate relationship between human carcinogenicity and exposure to captafol
 - One ecological case control study of pancreatic cancer and organochlorine agents (18 pesticides)
 - Non-significant increase in pancreatic cancer in residents living for >20 years in areas with high captafol usage



Sufficient Evidence from Studies in Experimental Animals

Tumors at multiple sites in mice

- Chronic feed studies in CD-1 mice (110 wks) (Quest *et al.* 1993)
 - Lymphosarcoma, hemangiosarcoma (heart, liver, spleen, and subcutis), Harderian gland adenoma (males)
- Chronic feed studies in B6C3F₁ mice (surviving at least 42 wks) (Ito *et al.* 1984)
 - Hemangioendothelioma (heart), hemangioma (spleen), and tumors of the small intestine and liver



Sufficient Evidence from Studies in Experimental Animals

Tumors at multiple sites in rats

- Chronic feed studies in Crl:CD rats (2 yrs) (Quest *et al.* 1993)
 - Kidney tumors (males); mammary gland fibroadenomas and neoplastic nodules in the liver (females)
- Chronic feed studies in F344 rats (2 yrs) (Tomano *et al.* 1990, Nyska *et al.* 1989)
 - Kidney tumors and neoplastic nodules in the liver




Mechanistic Evidence

- Proposed bioactivation pathways
- Genotoxic endpoints
- Other effects



Bioactivation

- Hydrolysis of N-S chemical bond
- Proposed episulfonium ion intermediate formed from the side-chain





Captafol is Genotoxic

Endpoint	Bacteria	Mammalian Cell Lines	<i>In Vivo</i>
Mutations	+	NT	+ (rat germ cell)
DNA single strand breaks		+	+
Sister chromatid exchange		+	NT
Chromosomal aberrations		+	NT
Micronucleus formation		+	+
Mitotic spindle disturbances		+	NT
Cell transformation		+	NT

NT = Not tested



Other Effects

- Cytotoxicity due to reaction of captafol with thiol-containing molecules such as glutathione and cysteine resulting in reduced cellular content of thiol groups
- Inhibition of enzymes involved in DNA replication and synthesis and RNA synthesis
- Induction of cytochrome P-450 monooxygenases



Proposed Captafol Listing

Captafol is *reasonably anticipated to be a human carcinogen* based on sufficient evidence of carcinogenicity from studies in experimental animals and supporting mechanistic data.